Cholinergic Drugs in Pharmacotherapy of Alzheimer's Disease

Authors: Camps P.; Munoz-Torrero D.

Source: Mini Reviews in Medicinal Chemistry, Volume 2, Number 1, February 2002 , pp. 11-25(15)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

Price: $63.10 plus tax (Refund Policy)

Abstract:

The cholinergic hypothesis of Alzheimer's disease has spurred the development of numerous structural classes of compounds with different pharmacological profiles aimed at increasing central cholinergic neurotransmission, thus providing a symptomatic treatment for this disease. Indeed, the only drugs currently approved for the treatment of Alzheimer's disease are cholinomimetics with the pharmacological profile of acetylcholinesterase inhibitors. Recent evidence of a potential disease modifying role of acetylcholinesterase inhibitors and M1 muscarinic agonists have led to a revival of this approach, which might be considered as more than a symptomatic treatment.

Keywords: Cholinergic Drugs; Alzheimers disease; muscarinic agonists; acetylcholine (ACh); Potassium Channel Blockers; Aminoacridines; N-Benzylpiperidines; xanomeline; muscarine

Language: English

Document Type: Review article

DOI: http://dx.doi.org/10.2174/1389557023406638

Publication date: 2002-02-01

More about this publication?

The aim of Mini-Reviews in Medicinal Chemistry is to publish short reviews on the important recent developments in medicinal chemistry and allied disciplines.

The scope of Mini-Reviews in Medicinal Chemistry will cover all areas of medicinal chemistry including developments in rational drug design, synthetic chemistry, bioorganic chemistry, high-throughput screening, combinatorial chemistry, drug targets, and natural product research and structure-activity relationship studies.

Mini-Reviews in Medicinal Chemistry is an essential journal for every medicinal and pharmaceutical chemist who wishes to be kept informed and up-to-date with the latest and most important developments.